ProQR Therapeutics N.V.
PRQR
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -57.25% | 61.97% | |||
| Total Other Revenue | -- | -15.54% | |||
| Total Revenue | -57.50% | 61.09% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -57.50% | 61.09% | |||
| SG&A Expenses | -2.41% | 24.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.92% | -3.14% | |||
| Operating Income | -47.91% | 19.73% | |||
| Income Before Tax | -47.92% | 19.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -47.91% | 19.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.91% | 19.30% | |||
| EBIT | -47.91% | 19.73% | |||
| EBITDA | -43.96% | 16.77% | |||
| EPS Basic | -47.87% | 19.25% | |||
| Normalized Basic EPS | -47.89% | 19.27% | |||
| EPS Diluted | -51.32% | 19.25% | |||
| Normalized Diluted EPS | -47.89% | 19.27% | |||
| Average Basic Shares Outstanding | 0.01% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||